You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR TYZEKA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TYZEKA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00640588 ↗ Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine Completed Novartis Pharmaceuticals Phase 3 2008-03-01 This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine
NCT00646503 ↗ Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B Completed Novartis Phase 4 2008-03-01 This study will explore efficacy and safety of Telbivudine in the fifth year of treatment.
NCT00651209 ↗ A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB) Completed Novartis Pharmaceuticals Phase 4 2008-02-01 This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve HBV DNA non-detectability.
NCT00710216 ↗ Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B Withdrawn Novartis Phase 4 1969-12-31 This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
NCT00710216 ↗ Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B Withdrawn University of Ulm Phase 4 1969-12-31 This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TYZEKA

Condition Name

Condition Name for TYZEKA
Intervention Trials
Hepatitis B, Chronic 4
Chronic Hepatitis B 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TYZEKA
Intervention Trials
Hepatitis 5
Hepatitis B, Chronic 5
Hepatitis B 5
Hepatitis, Chronic 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TYZEKA

Trials by Country

Trials by Country for TYZEKA
Location Trials
Germany 2
Spain 1
Brazil 1
Hong Kong 1
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TYZEKA

Clinical Trial Phase

Clinical Trial Phase for TYZEKA
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TYZEKA
Clinical Trial Phase Trials
Completed 3
Withdrawn 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TYZEKA

Sponsor Name

Sponsor Name for TYZEKA
Sponsor Trials
Novartis Pharmaceuticals 2
Novartis 2
University of Ulm 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TYZEKA
Sponsor Trials
Industry 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.